BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 20919968)

  • 21. Pneumococcal serotype evolution in Western Europe.
    Tin Tin Htar M; Christopoulou D; Schmitt HJ
    BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.
    Isaacman DJ; McIntosh ED; Reinert RR
    Int J Infect Dis; 2010 Mar; 14(3):e197-209. PubMed ID: 19700359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Invasive pneumococcal disease in the Northern Territory of Australia, 1994-1998.
    Krause VL; Reid SJ; Merianos A
    Med J Aust; 2000 Oct; 173(S2):S27-31. PubMed ID: 11062803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are current recommendations for pneumococcal vaccination appropriate for Western Australia? The Vaccine Impact Surveillance Network--Invasive Pneumococcal Study Group.
    Med J Aust; 2000 Oct; 173(S2):S36-40. PubMed ID: 11062805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Invasive pneumococcal disease in Australia, 2009 and 2010.
    Bareja C; Toms C; Lodo K; de Kluyver R;
    Commun Dis Intell Q Rep; 2015 Jun; 39(2):E265-79. PubMed ID: 26234260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The epidemiology of invasive pneumococcal disease in children in Far North Queensland.
    Fagan RL; Hanna JN; Messer RD; Brookes DL; Murphy DM
    J Paediatr Child Health; 2001 Dec; 37(6):571-5. PubMed ID: 11903838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing the impact of pneumococcal conjugate vaccines on invasive pneumococcal disease using polymerase chain reaction-based surveillance: an experience from South Africa.
    Tempia S; Wolter N; Cohen C; Walaza S; von Mollendorf C; Cohen AL; Moyes J; de Gouveia L; Nzenze S; Treurnicht F; Venter M; Groome MJ; Madhi SA; von Gottberg A
    BMC Infect Dis; 2015 Oct; 15():450. PubMed ID: 26496761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreasing incidence and changes in serotype distribution of invasive pneumococcal disease in persons aged under 18 years since introduction of 10-valent and 13-valent conjugate vaccines in Portugal, July 2008 to June 2012.
    Aguiar SI; Brito MJ; Horacio AN; Lopes JP; Ramirez M; Melo-Cristino J; ;
    Euro Surveill; 2014 Mar; 19(12):20750. PubMed ID: 24698140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
    Lacapa R; Bliss SJ; Larzelere-Hinton F; Eagle KJ; McGinty DJ; Parkinson AJ; Santosham M; Craig MJ; O'Brien KL
    Clin Infect Dis; 2008 Aug; 47(4):476-84. PubMed ID: 18627249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pediatric invasive pneumococcal disease in Taiwan following a national catch-up program with the 13-valent pneumococcal conjugate vaccine.
    Wei SH; Chiang CS; Chiu CH; Chou P; Lin TY
    Pediatr Infect Dis J; 2015 Mar; 34(3):e71-7. PubMed ID: 25247584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early Changes in the Serotype Distribution of Invasive Pneumococcal Isolates from Children after the Introduction of Extended-valent Pneumococcal Conjugate Vaccines in Korea, 2011-2013.
    Cho EY; Choi EH; Kang JH; Kim KH; Kim DS; Kim YJ; Ahn YM; Eun BW; Oh SH; Cha SH; Cho HK; Hong YJ; Kim KN; Kim NH; Kim YK; Kim JH; Lee H; Lee T; Kim HM; Lee KS; Kim CS; Park SE; Kim YM; Oh CE; Ma SH; Jo DS; Choi YY; Lee J; Bae GR; Park O; Park YJ; Kim ES; Lee HJ
    J Korean Med Sci; 2016 Jul; 31(7):1082-8. PubMed ID: 27366006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repeat pneumococcal polysaccharide vaccine in Indigenous Australian adults is associated with decreased immune responsiveness.
    Moberley S; Licciardi PV; Balloch A; Andrews R; Leach AJ; Kirkwood M; Binks P; Mulholland K; Carapetis J; Tang MLK; Skull S
    Vaccine; 2017 May; 35(22):2908-2915. PubMed ID: 28455171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
    De Wals P; Lefebvre B; Deceuninck G; Longtin J
    Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
    Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
    Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
    Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality.
    Harboe ZB; Dalby T; Weinberger DM; Benfield T; Mølbak K; Slotved HC; Suppli CH; Konradsen HB; Valentiner-Branth P
    Clin Infect Dis; 2014 Oct; 59(8):1066-73. PubMed ID: 25034421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Laboratory surveillance of invasive pneumococcal disease in Australia, 2003 predicting the future impact of the universal childhood conjugate vaccine program.
    Watson M; Roche P; Bayley K; Bell JM; Collignon P; Gilbert GL; Hogg G; Keil AD; Krause V; Murphy D; Smith HV; Brown M; Stylianopoulos J; Turnidge J
    Commun Dis Intell Q Rep; 2004; 28(4):455-64. PubMed ID: 15745392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Have changing pneumococcal vaccination programmes impacted disease in Ontario?
    Lim GH; Wormsbecker AE; McGeer A; Pillai DR; Gubbay JB; Rudnick W; Low DE; Green K; Crowcroft NS; Deeks SL
    Vaccine; 2013 May; 31(24):2680-5. PubMed ID: 23597716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017.
    Wijayasri S; Hillier K; Lim GH; Harris TM; Wilson SE; Deeks SL
    PLoS One; 2019; 14(12):e0226353. PubMed ID: 31834926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in Singapore children, 2005 through 2010.
    Thoon KC; Chong CY; Tee NW
    Int J Infect Dis; 2012 Mar; 16(3):e209-15. PubMed ID: 22281191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.